Advanced

FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.

Brun, Eva LU ; Kjellén, Elisabeth LU ; Tennvall, Jan LU ; Ohlsson, Tomas G LU ; Sandell, Anders LU ; Perfekt, Roland LU ; Wennerberg, Johan LU and Strand, Sven-Erik LU (2002) In Head and Neck 24(2). p.127-135
Abstract
BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete... (More)
BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics, Female, Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy, Human, Male, Middle Age, Predictive Value of Tests, Reproducibility of Results, Radiopharmaceuticals/*diagnostic use/pharmacokinetics, Squamous Cell/mortality/*radionuclide imaging/*therapy, Carcinoma, 80 and over, Aged
in
Head and Neck
volume
24
issue
2
pages
127 - 135
publisher
John Wiley & Sons
external identifiers
  • pmid:11891942
  • wos:000173623500003
  • scopus:0036154720
ISSN
1043-3074
DOI
10.1002/hed.10037
language
English
LU publication?
yes
id
5cb8efc7-dd78-4119-8426-fbcad0dbd082 (old id 106026)
alternative location
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11891942&dopt=Abstract
date added to LUP
2007-07-18 15:44:12
date last changed
2017-10-29 03:33:50
@article{5cb8efc7-dd78-4119-8426-fbcad0dbd082,
  abstract     = {BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc.},
  author       = {Brun, Eva and Kjellén, Elisabeth and Tennvall, Jan and Ohlsson, Tomas G and Sandell, Anders and Perfekt, Roland and Wennerberg, Johan and Strand, Sven-Erik},
  issn         = {1043-3074},
  keyword      = {Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics,Female,Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy,Human,Male,Middle Age,Predictive Value of Tests,Reproducibility of Results,Radiopharmaceuticals/*diagnostic use/pharmacokinetics,Squamous Cell/mortality/*radionuclide imaging/*therapy,Carcinoma,80 and over,Aged},
  language     = {eng},
  number       = {2},
  pages        = {127--135},
  publisher    = {John Wiley & Sons},
  series       = {Head and Neck},
  title        = {FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.},
  url          = {http://dx.doi.org/10.1002/hed.10037},
  volume       = {24},
  year         = {2002},
}